Chiesi Farmaceutici backs gene therapy commercialisation deal with $39.8m equity and collaboration financing.
UniQure, a Netherlands-based gene therapy company, has received €14m ($18m) in equity financing from Chiesi Famaceutici, an Italy-based therapeutics and specialist medicine company. The investment by Chiesi results in the conversion into new UniQure shares of €14.1m ($18.1m) in convertible debt which UniQure recently raised from private equity firm Coller Capital and existing financial investors including Forbion Capital Partners, Gilde Healthcare Partners, Lupus Alpha and Grupo Netco.
The equity financing transaction, together with €17m ($21.8m) in collaboration financing from Chiesi…
